Somewhat Favorable Press Coverage Somewhat Unlikely to Affect AMAG Pharmaceuticals (AMAG) Share Price

News stories about AMAG Pharmaceuticals (NASDAQ:AMAG) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AMAG Pharmaceuticals earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 46.1936607375079 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:

A number of equities research analysts recently commented on AMAG shares. Janney Montgomery Scott upgraded shares of AMAG Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the company from $16.65 to $45.00 in a research report on Thursday, February 15th. B. Riley restated a “hold” rating and issued a $16.00 price objective on shares of AMAG Pharmaceuticals in a research report on Monday, January 29th. ValuEngine downgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Leerink Swann restated a “market perform” rating on shares of AMAG Pharmaceuticals in a research report on Friday, February 2nd. Finally, Piper Jaffray restated a “hold” rating and issued a $15.00 price objective on shares of AMAG Pharmaceuticals in a research report on Thursday, January 18th. Eleven analysts have rated the stock with a hold rating and three have given a buy rating to the company. AMAG Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $23.91.



AMAG stock opened at $21.20 on Thursday. AMAG Pharmaceuticals has a 12-month low of $11.93 and a 12-month high of $24.85. The company has a debt-to-equity ratio of 0.93, a current ratio of 1.74 and a quick ratio of 1.60. The company has a market cap of $710.75, a PE ratio of -3.71 and a beta of 0.09.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.68. AMAG Pharmaceuticals had a negative net margin of 32.66% and a positive return on equity of 0.96%. The company had revenue of $158.30 million during the quarter, compared to the consensus estimate of $158.84 million. During the same period last year, the firm earned ($0.31) EPS. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. analysts forecast that AMAG Pharmaceuticals will post -3.25 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect AMAG Pharmaceuticals (AMAG) Share Price” was originally published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://dakotafinancialnews.com/2018/04/12/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-amag-pharmaceuticals-amag-share-price.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Insider Buying and Selling by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply